Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: Rofecoxib in experimental colon cancer

References

• Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001;127:411–7.
   PubMed Web of Science ®Google Scholar
• Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960–8.
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Palmer JR, Zauber AG, Wershaver ME, Stolley PD, Shapio S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355–8.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293–7.
   PubMed Web of Science ®Google Scholar
• Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409–12.
   PubMed Web of Science ®Google Scholar
• Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60: 5040–4.
   Google Scholar
• Kishimoto Y, Takata N, Jinnai T, Morisawa T, Shiota G, Kawasaki H, et al. Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut 2000;47:812–9.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Fukutake M, Yokota S, Ishida K, Wakabayashi K, Sugimura T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J Cancer Res Clin Oncol 1996;122:219–22.
   PubMed Web of Science ®Google Scholar
• Kishimoto Y, Yashima K, Morisawa T, Shiota G, Kawasaki H, Hasegawa J. Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. J Gastroenterol 2002;37:186–93.
   PubMed Web of Science ®Google Scholar
• Li H, Kramer PM, Lubet RA, Steele VE, Kelloff GJ, Pereira MA. Termination ofpiroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. Cancer Lett 1999;147:187–93.
   PubMed Web of Science ®Google Scholar
• Roy HK, Karolski WJ, Ratashak A. Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer 2001;92:609–15.
   Google Scholar
• McKenna F. COX-2: Separating myth from reality. Scand J Rheumatol 1999;109:19–29.
   Web of Science ®Google Scholar
• Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 2001;36: 865–9.
   Google Scholar
• Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, et al. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187:295–301.
   PubMed Web of Science ®Google Scholar
• Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823–6.
   PubMed Web of Science ®Google Scholar
• Sheehan KM, Sheahan K, O’Donoghue DP, MacSweenwy F, Conroy RM, Fitzerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282: 1254–7.
   Google Scholar
• Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002;45:98–103.
   PubMed Web of Science ®Google Scholar
• Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803–9.
   PubMed Web of Science ®Google Scholar
• Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996;111:1134–40.
   PubMed Web of Science ®Google Scholar
• DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259–62.
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563–8.
   PubMed Web of Science ®Google Scholar
• Depre M, Ehrich E, Van Hecken A, De Lepeleire I, Dallob A, Wong P, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000;56: 167–74.
   Google Scholar
• Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733–40.
   PubMed Web of Science ®Google Scholar
• Maskens AP. Histogenesis and growth pattern of 1,2 dimethylhydrazine-induced rat colon adenocarcinoma. Cancer Res 1976;36:1585–92.
   PubMed Web of Science ®Google Scholar
• Chan CC, Boyce S, Brideau C, Charleson S, Cronlish W, Ethier D, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methyl sulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551–60.
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Vogelstein B, Kudo S, Riboli E, Nakamura S, Hainaut P, et al. Carcinoma of the colon and rectum. In: Hamilton SR, Aaltonen LA, editors. WHO Classification of tumours. Pathology and genetics of tumors of the digestive system. Lyon: IARC Press; 2000. p 111.
   Google Scholar
• Betton GR, Whiteley LO, Anver MR, Brown R, Deschl U, Elwell M, et al. Gastrointestinal tract. In: Mohr U, editor. International classification of rodent tumors: the mouse. Berlin: Springer; 2001. pp 52–6.
   Google Scholar
• Dukes CE, Bussey HJR. The spread of cancer and its effect on prognosis. Cancer 1958;181:225–36.
   Google Scholar
• Bissonnette M, Khare S, von Lintig FC, Wali RK, Nguyen L, Zhang Y, et al. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cycloxygenase-2, and cyclin D1. Cancer Res 2000;60:4602–9.
   PubMed Web of Science ®Google Scholar
• Vivona AA, Shpitz B, Medline A, Bruce WR, Hay K, Ward MA, et al. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 1993;14:1777–81.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Fukuda K, Sugimura T, Walabayashi K. Beta catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res 1998;58:42–6.
   PubMed Web of Science ®Google Scholar
• Ravnik-Glavac M, Cerar A, Glavac D. Animal model in the study of colorectal carcinogenesis. Pflugers Arch 2000;440 Suppl 5:R55–7.
   Google Scholar
• Luceri C, De Filippo C, Caderni G, Gambacciani L, Salvadori M, Giannini A, et al. Detection of somatic DNA alterations in azoxymethane-induced F344 rat colon tumors by random amplified polymorphic DNA analysis. Carcinogenesis 2000;24:1753–6.
   Web of Science ®Google Scholar
• Yuan P, Sun MH, Zhang JS, Zhu XZ, Shi DR. APC and Kras gene mutation in aberrant crypt foci of human colon. World J Gastroenterol 2001;7:352–6.
   Google Scholar
• Nucci MR, Robinson CR, Longo P, Campbell P, Hamilton SR. Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Hum Pathol 1997;28:1396–407.
   Google Scholar
• Paulsen JE, Namork E, Steffensen IL, Eide TJ, Alexander J. Identification and quantification of aberrant crypt foci in the colon of Min mice: a murine model of familial adenomatous polyposis. Scand J Gastroenterol 2000;35:534–9.
   Google Scholar
• Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991; 22:287–94.
   Google Scholar
• Shipitz B, Bomstein Y, Mekori Y, Cohen R, Kaufman Z, Neufeld D, et al. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol 1998;29:469–75.
   PubMed Web of Science ®Google Scholar
• Classen M. Chemoprevention of colorectal cancer with ASS, NSAIDs, and cyclooxygenase-2 inhibitors. World Gastroenterology News 2000;5:21–4.
   Google Scholar
• Charalambous D, O’Brien PE. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J Gastroenterol Hepatol 1996;11:307–10.
   PubMed Web of Science ®Google Scholar
• Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, et al. Sulindac sulphone inhibits azoxymethane induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909–15.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Mutoh M, Kawamori T, Sugimura T, Wakabayashi K. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxy methane-induced rat colon carcinogenesis. Carcinogenesis 2000;21: 1319–27.
   Google Scholar
• Tsujii M, Kawano S, Tsujii S, Sawoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705–16.
   PubMed Web of Science ®Google Scholar
• Laudanno OM, Cesolari JA, Esnarriaga J, Rista L, Piombo G, Maglione C, et al. Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci 2001;46:779–84.
   PubMed Web of Science ®Google Scholar
• Guo JS, Cho CH, Lam Liu ES, Choy HT, Wang JY, Leung Koo MW. Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. Toxicol Appl Pharmacol 2002;183: 41–5.
   Google Scholar
• Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T, et al. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant induced arthritis. J Pharmacol Exp Ther 2002;303:503–9.
   PubMed Web of Science ®Google Scholar
• Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br Med J 2002;325:624.
   PubMed Web of Science ®Google Scholar